SAB Biotherapeutics, Inc. SEC filings SABS
SAB Biotherapeutics, Inc. has 433 filings in SEC EDGAR's recent list, going back to Dec 7, 2020. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Aug 21, 2026 | — |
| S-8 | Employee stock plan registration | Mar 31, 2026 | — |
| 424B5 | Prospectus supplement | Mar 19, 2026 | — |
| 424B5 | Prospectus supplement | Mar 17, 2026 | — |
| S-3 | Shelf registration | Dec 29, 2025 | — |
| S-8 | Employee stock plan registration | Dec 15, 2025 | — |
| 424B3 | Prospectus | Nov 12, 2025 | — |
| S-3/A | Filing | Sep 22, 2025 | — |
| S-3 | Shelf registration | Sep 2, 2025 | — |
| S-8 | Employee stock plan registration | Apr 3, 2025 | — |
| S-8 | Employee stock plan registration | Aug 12, 2024 | — |
| S-8 | Employee stock plan registration | Feb 23, 2024 | — |
| 424B5 | Prospectus supplement | Jan 26, 2024 | — |
| S-3/A | Filing | Nov 20, 2023 | — |
| S-3 | Shelf registration | Nov 3, 2023 | — |
| S-3 | Shelf registration | Aug 21, 2023 | — |
| POS AM | Form pos am | Jul 10, 2023 | — |
| S-3 | Shelf registration | May 9, 2023 | — |
| S-3 | Shelf registration | May 1, 2023 | — |
| 424B3 | Prospectus | Mar 7, 2023 | — |
| S-3 | Shelf registration | Feb 3, 2023 | — |
| POS AM | Form pos am | Feb 3, 2023 | — |
| 424B3 | Prospectus | Nov 18, 2022 | — |
| S-1 | Registration statement | Aug 23, 2022 | — |
| 424B3 | Prospectus | Aug 17, 2022 | — |
| 424B3 | Prospectus | Jun 7, 2022 | — |
| 424B3 | Prospectus | May 16, 2022 | — |
| 424B3 | Prospectus | Apr 29, 2022 | — |
| POS AM | Filing | Apr 20, 2022 | — |
| S-8 | Employee stock plan registration | Feb 1, 2022 | — |
| 424B3 | Prospectus | Dec 29, 2021 | — |
| S-1 | Registration statement | Dec 3, 2021 | — |
| 424B3 | Prospectus | Sep 24, 2021 | — |
| 424B3 | Prospectus | Sep 23, 2021 | — |
| S-4/A | Filing | Sep 22, 2021 | — |
| S-4/A | Filing | Sep 8, 2021 | — |
| S-4 | Registration for a merger or exchange | Aug 17, 2021 | — |
| 424B4 | Prospectus | Jan 12, 2021 | — |
| S-1/A | Amended registration statement | Jan 7, 2021 | — |
| S-1/A | Amended registration statement | Jan 4, 2021 | — |
| S-1 | Registration statement | Dec 7, 2020 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SABS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1833214
- Former names
- Big Cypress Acquisition Corp. (until Oct 22, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.